低剂量产前倍他米松在绵羊妊娠模型中实现与世卫组织地塞米松方案等效的早产肺成熟且内分泌干扰更小
在绵羊妊娠模型中,产前低剂量倍他米松方案(4次2 mg肌注,每12小时一次)与世卫组织地塞米松方案(4次6 mg肌注,每12小时一次)相比,早产羔羊肺功能改善等效,但母胎血浆中性粒细胞、葡萄糖、胎儿C肽升高及胎儿IGF-1降低等内分泌干扰更小。
要点
- 低剂量倍他米松组与地塞米松组在通气30分钟后肺功能改善等效,均显著优于生理盐水对照组。
- 地塞米松组母胎血浆中性粒细胞、葡萄糖及胎儿C肽显著高于倍他米松组,胎儿IGF-1显著降低。
- 倍他米松组中胎儿ACTH、母体血糖和胎儿血糖与母体体重相关,提示按体重调整剂量可能减少HPA轴干扰。
核心结论
- 在早产羔羊中,8 mg倍他米松低剂量方案达到与24 mg地塞米松方案等效的肺成熟,但对母胎下丘脑-垂体-肾上腺轴扰动更小。
- 鉴于绵羊与人类药代动力学差异,2 mg倍他米松剂量可能仍高于早产肺稳健成熟所需的最低剂量。
- 按母体体重调整倍他米松剂量可能是减少母胎HPA轴扰动的关键。
研究设计与样本
- 经伦理审查批准后,采用日期匹配的单胎妊娠母羊,随机接受三种肌注方案之一。
- 地塞米松组:4次6 mg地塞米松磷酸盐肌注,每12小时一次(n=22)。
- 倍他米松组:4次2 mg倍他米松磷酸盐肌注,每12小时一次(n=21)。
- 生理盐水对照组:4次2 mL生理盐水肌注,每12小时一次(n=16)。
- 首次注射后48小时(124±1天)分娩羔羊,通气30分钟后安乐死采样。
主要发现
- 通气30分钟后,两个激素组肺功能较生理盐水对照组均显著且等效改善(P<.05)。
- 动脉血pH、pO2、pCO2、肺顺应性、通气效率指数及40 cmH2O静压下的肺容积组间无显著差异。
- 两组激素组间表面活性蛋白Sp-a、Sp-b、Sp-c、Sp-d及水通道蛋白Aqp1、Aqp5和钠通道上皮1β亚基(Scnn1b)mRNA表达等效。
- 地塞米松组母体和胎儿血浆中性粒细胞、葡萄糖及胎儿血浆C肽显著高于倍他米松组;胎儿血浆IGF-1显著低于倍他米松组(P<0.05)。
- 倍他米松组中胎儿ACTH(r=0.53)、母体血糖(r=-0.52)和胎儿血糖(r=-0.42)与母体体重相关(P<.05),胎儿pCO2和pO2无相关性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The intramuscular administration of antenatal steroids to women at risk of preterm delivery achieves high maternal and fetal plasma steroid concentrations, which are associated with adverse effects and may reduce treatment efficacy. We have demonstrated that antenatal steroid efficacy is independent of peak maternofetal steroid levels once exposure is maintained above a low threshold. OBJECTIVE: This study aimed to test, using a sheep model of pregnancy, whether the low-dose antenatal steroid regimen proposed as part of the Antenatal Corticosteroids for Improving Outcomes in Preterm Newborns trial would achieve preterm lung maturation equivalent to that of the existing World Health Organization dexamethasone treatment regimen, but with reduced risk of adverse outcomes. STUDY DESIGN: Following ethical review and approval, date-mated ewes with single fetuses received intramuscular injections of either (1) four 6-mg maternal intramuscular injections of dexamethasone phosphate every 12 hours (n=22), (2) 4 2-mg maternal intramuscular injections of betamethasone phosphate every 12 hours (n=21), or (3) 4 2-mL maternal intramuscular injections of saline every 12 hours (n=16). Of note, 48 hours after first injection, (124±1 day), lambs were delivered, ventilated for 30 minutes, and euthanized for sampling. Arterial blood gas, respiratory, hematological, and biochemical data were analyzed for between-group differences with analysis of variance according to distribution and variance, with P<.05 taken as significant. RESULTS: After 30 minutes of ventilation, lambs from both steroid-treated groups had significant and equivalent improvements in lung function relative to saline control (P<.05). There was no significant difference in arterial blood pH, pO2, pCO2, lung compliance, ventilator efficiency index, or lung volume at necropsy with a static pressure of 40 cmH2O. The messenger RNA expression of surfactant protein (Sp)a, Spb, Spc, Spd, aquaporin (Aqp)1, Aqp5, and sodium channel epithelial 1 subunit beta (Scnn1b) was equivalent between both steroid groups. Maternal and fetal plasma neutrophil, glucose, and fetal plasma C-peptide levels were significantly elevated in the dexamethasone group, relative to the betamethasone group. Fetal plasma insulin-like growth factor 1 was significantly reduced in the dexamethasone group compared with the betamethasone group (P<0.05). Fetal adrenocorticotropic hormone (r=0.53), maternal glucose value (r=-0.52), and fetal glucose values (r=-0.42) were correlated with maternal weight in the betamethasone group (P<.05), whereas fetal pCO2 and pO2 were not correlated. There was no significant difference between male and female lamb outcomes in any groups for any of the items evaluated. CONCLUSION: This study reported that in preterm lambs, a low-dose treatment regimen of 8 mg betamethasone achieves lung maturation equivalent to that of a 24-mg dexamethasone-based regimen, but with smaller perturbations to the maternofetal hypothalamic-pituitary-adrenal axis. These data suggested that given steroid pharmacokinetic differences between sheep and humans, a betamethasone dose of 2 mg may remain above the minimum dose necessary for robust maturation of the preterm lung. Maternal weight-adjusted betamethasone doses might also be a key to reducing perturbations to the maternofetal hypothalamic-pituitary-adrenal axis.
引用
- Usuda H, Fee EL, Carter S, et al. Low-dose antenatal betamethasone treatment achieves preterm lung maturation equivalent to that of the World Health Organization dexamethasone regimen but with reduced endocrine disruption in a sheep model of pregnancy. Am J Obstet Gynecol. 2022. PMID: 35792176. doi:10.1016/j.ajog.2022.06.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。